# Merck Announces Positive Phase 3 Cancer Trial Results Ahead of Investor Event

- URL: https://stocks.freetheai.org/news/merck-announces-positive-phase-3-cancer-trial-results-ahead-of-investor-event-7653ee
- Published: 2026-10-14T07:00:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [NYSE:MRK](https://stocks.freetheai.org/symbols/NYSE-MRK)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Merck & Co., Inc. (MRK) announced positive Phase 3 trial results demonstrating improved survival for its drug candidate SAC-TMT in treating endometrial cancer. The study findings were presented at the ESMO 2026 conference. Additionally, the drugmaker is sharing initial Phase 3 data from the INTerpath-001 trial, which evaluates mRNA-4157 combined with KEYTRUDA as an adjuvant therapy for resected stage IIB–IV melanoma during an ESMO Presidential Symposium.

These clinical developments advance key areas of the drugmaker's oncology portfolio. In corporate updates, Paul J. Diaz will join the board of directors effective November 1, 2026, expanding the board to 14 seats. Diaz will serve on the Audit and Research Committees before standing for election at the May 2027 shareholder meeting.

Investors can follow further strategy updates during an Oncology Investor Event and live webcast scheduled for October 26, 2026, during the ESMO meeting in Madrid. Shares of Merck & Co., Inc. (NYSE:MRK) were trading at $142 USD, down 2.39% for the day.

## Key points

- Phase 3 trial results showed SAC-TMT improved survival in endometrial cancer at ESMO 2026.
- Initial Phase 3 INTerpath-001 data was presented for mRNA-4157 plus KEYTRUDA in melanoma.
- Merck will host an Oncology Investor Event and webcast on October 26, 2026.
- Paul J. Diaz joins the board of directors on November 1, 2026, expanding it to 14 seats.
- Merck shares fell 2.39% to $142 USD.

## Questions and answers

### What were the Phase 3 trial results for Merck's SAC-TMT?

Phase 3 trial results showed that SAC-TMT improved survival in patients with endometrial cancer, presented at ESMO 2026.

### When is the Merck Oncology Investor Event?

Merck will host its Oncology Investor Event on October 26, 2026, in conjunction with the ESMO conference in Madrid.

### Who is joining the Merck board of directors?

Paul J. Diaz joins the board effective November 1, 2026, expanding it to 14 members and serving on the Audit and Research Committees.